Kobe, Japan

Takehiko Tozyo

This inventor holds 2 USPTO granted patents. Top assignee: Shionogi Company Limited. Active years: 1995-1996.

IDiyas Innovation Intelligence. (2026). Inventor Profile: Takehiko Tozyo. Retrieved from https://idiyas.com/inventor/takehiko-tozyo

Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile


% Patents Active = 100.0

Average Co-Inventor Count = 5.0

ph-index = 2

Forward Citations = 12(Granted Patents)


Company Filing History:


Years Active: 1995-1996

Loading Chart...
2 patents (USPTO):Explore Patents

Title: Takehiko Tozyo: Innovator in Triterpene Derivatives

Introduction

Takehiko Tozyo is a notable inventor based in Kobe, Japan. He has made significant contributions to the field of pharmaceuticals, particularly in the development of triterpene derivatives and endothelin-receptor antagonists. With a total of 2 patents to his name, Tozyo's work is recognized for its potential in treating diseases associated with excessive secretion of endothelin.

Latest Patents

Tozyo's latest patents focus on triterpene derivatives that exhibit anti-endothelin activities. These compounds are designed to be useful in the prophylaxis and treatment of various diseases. The patents detail the chemical formulas and structures of these derivatives, emphasizing their therapeutic potential.

Career Highlights

Tozyo is currently associated with Shionogi Company Limited, where he continues to innovate and contribute to the pharmaceutical industry. His work has garnered attention for its scientific rigor and practical applications in medicine.

Collaborations

Throughout his career, Tozyo has collaborated with esteemed colleagues, including Toshiro Konoike and Yoshitaka Araki. These partnerships have further enhanced the impact of his research and development efforts.

Conclusion

Takehiko Tozyo stands out as a significant figure in the realm of pharmaceutical innovations. His contributions to triterpene derivatives and endothelin-receptor antagonists highlight his commitment to advancing medical science.

Profile summary based on public USPTO records.
Data Sources: USPTO Patent Grant XML, Patent Center, EPO & CIPO • Normalized by IDiyas Innovation Graph. Methodology & provenance architecturePlease report any incorrect information to [email protected]
Loading…